Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
Takeaways: Health Canada’s go‑ahead for Devonian’s seamless Phase II/III pediatric Thykamine program positions the company to enter a crowded but fast‑growing non‑steroidal topica...
